StockData

NovelStem International Corp. (NSTM) stock

NSTMOTCRetail-Retail Stores, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.01+0.00 (0.00%)

Close on Oct 19, 2026Market cap $493.32KP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$493.32K
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$307.56K
EPS, diluted
$0.00
Book value per share
-$0.04
Diluted shares
49M

Trading

Previous close
$0.01
Open
$0.01
Day's range
$0.01 – $0.01
Volume
0

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodNSTMS&P 500DifferenceNSTM per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months0.0%+3.4%−3.4 pts
Year to date0.0%+13.3%−13.3 pts
1 year-50.0%+16.6%−66.6 pts
3 years-92.3%+86.4%−178.7 pts-57.5%+23.1%
5 years-96.7%+81.9%−178.5 pts-49.4%+12.7%
10 years-98.7%+318.9%−417.5 pts-35.1%+15.4%

Eleven years at a glance

Fiscal years 2008 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$120.11K

Net income

-$307.56K

EPS, diluted

$0.00-100.0% YoY

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases NovelStem International filed with the SEC as exhibits to Form 8-K or 6-K

About NovelStem International

Retail-Retail Stores, NEC

NovelStem International Corp. operates as a holding company focused on biotechnology assets. The company previously held an equity stake in NewStem Ltd, a development-stage Israeli biotech company specializing in human pluripotent stem cells for oncology drug discovery and cancer diagnostics. Following NewStem’s liquidation and the sale of its interest in the NetCo joint venture, NovelStem’s primary asset consists of rights to future licensing proceeds and profits from proprietary stem cell technology relicensed by Yissum Research Development Company. Potential customers for this technology comprise healthcare institutions, oncologists, and pharmaceutical licensees.

Company profile, executives and history

NovelStem International stock: common questions

What is NovelStem International's stock price?

NSTM closed at $0.01 on Oct 19, 2026, up 0.00% on the day.

What is NovelStem International's market cap?

NovelStem International was worth $493.32K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is NSTM's P/E ratio?

NovelStem International lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

Does NovelStem International pay a dividend?

No. NovelStem International has not paid a cash dividend over the last twelve months.

How has NSTM stock performed over the past year?

Including dividends, NSTM returned -50.0% over the past year, against +16.6% for the S&P 500.

Who are NovelStem International's competitors?

Companies most similar to NovelStem International by business, industry and size include RMTG, RCT, NEGG, RERE, BQ.

See a number that looks wrong?